Duchenne Muscular Dystrophy (DMD) influences millions globally, necessitating a robust market for effective treatments. The present DMD treatment landscape is characterized by the focus on symptom management and supportive care. However, recent breakthroughs in gene therapy and drugs are creating the way for promising curative solutions. Clinical